Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration and diabetic macular edema. Patients with these conditions are increasingly being prescribed Regeneron Pharmaceuticals' (NASDAQ: REGN) Eylea, and as a result, Eylea's selling at a $6 billion annualized clip globally.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss Eylea's success and how Regeneron Pharmaceuticals' plans to maintain market leadership in these indications in the future.
A full transcript follows the video.
Source: Fool.com
Regeneron Pharmaceuticals Inc. Aktie
1.021,0 €
-1,50 %
Die Regeneron Pharmaceuticals Inc. Aktie zieht viel Aufmerksamkeit auf sich: Viel mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 1085 € für Regeneron Pharmaceuticals Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 1021.0 €.
